Glaucoma

Top Story

Inotek receives US patent for trabodenoson, prostaglandin analogue for reduction of IOP

July 25, 2016

The United States Patent and Trademark Office has issued a composition of matter patent for trabodenoson in combination with a prostaglandin analogue for reducing IOP in patients with glaucoma, according to a press release.

U.S. patent No. 9,370,530 includes composition of matter intellectual property protection for the use of trabodenoson (Inotek) in combination with a prostaglandin analogue until 2031. The patent also includes composition of matter patents covering the trabodenoson compound in the U.S. until 2026 and abroad until 2025, and the crystalline formulation of trabodenoson used in eye drops in the U.S. until 2033.

Perspectives on Glaucoma

ONO-9054 lowers IOP in early primary OAG, OHT

July 22, 2016
Researchers reported lower intraocular pressure in subjects with early primary open-angle glaucoma or ocular hypertension following single and multiple day dosing with…

FDA raises concerns about manufacturing facility in latanoprostene bunod complete response letter to Valeant

July 22, 2016
Valeant received a complete response letter from the FDA regarding the new drug application for latanoprostene bunod ophthalmic solution 0.024%, a once-daily topical eye…
Perspectives on Glaucoma

Study: Perimetry detects progression before photography in eyes with field loss

July 21, 2016
Progression in the visual field was detected first, more than four times as often as progression in the optic disc, in patients with manifest glaucoma, according to…
In the Journals

Macular carotenoids can have positive effects on visual function

July 19, 2016
Researchers found that in subjects free of retinal disease and with low macular pigment, supplementation with a…
More »
Meeting News Coverage

Latanoprostene bunod reduces IOP, ocular hypertension

July 20, 2016
BOSTON – Once daily latanoprostene bunod 0.024%, taken in the evening, reduced IOP in subjects with open angle…
More »
Featured
Optometry's Meeting 2016

Optometry's Meeting 2016

Perspectives on Glaucoma

Study: Perimetry detects progression before photography in eyes with field loss

July 21, 2016
Progression in the visual field was detected first, more than four times as often as progression in the optic disc, in…
More »

Inotek receives US patent for trabodenoson, prostaglandin analogue for reduction of IOP

July 25, 2016
The United States Patent and Trademark Office has issued a composition of matter patent for trabodenoson in combination with a prostaglandin analogue…

Perspectives on Glaucoma

ONO-9054 lowers IOP in early primary OAG, OHT

July 22, 2016
Researchers reported lower intraocular pressure in subjects with early primary open-angle glaucoma or ocular hypertension following single and…

FDA raises concerns about manufacturing facility in latanoprostene bunod complete response letter to Valeant

July 22, 2016
Valeant received a complete response letter from the FDA regarding the new drug application for latanoprostene bunod ophthalmic solution 0.024%, a…

Perspectives on Glaucoma

Study: Perimetry detects progression before photography in eyes with field loss

July 21, 2016
Progression in the visual field was detected first, more than four times as often as progression in the optic disc, in patients with manifest…

Meeting News Coverage

Latanoprostene bunod reduces IOP, ocular hypertension

July 20, 2016
BOSTON – Once daily latanoprostene bunod 0.024%, taken in the evening, reduced IOP in subjects with open angle glaucoma or ocular hypertension…

VideoFrom OSN Europe

Five most-viewed videos from EGS

July 18, 2016
The most trending articles on Healio.com/OSN from the European Glaucoma Society Congress were video perspectives from key opinion leaders who shared…

In the Journals

Laser goniopuncture may enhance IOP lowering of previous surgery

July 14, 2016
Laser goniopuncture can contribute to IOP reduction after viscocanalostomy or phacoviscocanalostomy, according to a study. Laser goniopuncture is a…

Inotek initiates phase 2 trial for fixed-dose combination of trabodenoson, latanoprost

July 14, 2016
Inotek Pharmaceuticals has initiated a phase 2 dose-ranging trial of a fixed-dose combination of trabodenoson and latanoprost for the treatment of…

In the Journals

LUNAR study: Latanoprostene bunod non-inferior to timolol over 3 months

July 6, 2016
Latanoprostene bunod was shown to be non-inferior to timolol in treating patients with open-angle glaucoma or ocular hypertension, according to…

Meeting News CoverageFrom OSN Europe

Glaucoma diagnosis challenging when associated with myopia

July 5, 2016
OVIEDO, Spain — Glaucoma and myopia often coexist, making management challenging, according to a speaker at the second European Meeting of…

More Headlines »
morganatic-roan